{"id":5402,"date":"2025-03-17T17:10:00","date_gmt":"2025-03-17T11:40:00","guid":{"rendered":"https:\/\/trending.niftytrader.in\/?p=5402"},"modified":"2025-05-27T12:21:12","modified_gmt":"2025-05-27T06:51:12","slug":"astrazeneca-to-buy-esobiotec-for-1b-to-boost-cell-therapy","status":"publish","type":"post","link":"https:\/\/www.niftytrader.in\/markets\/astrazeneca-to-buy-esobiotec-for-1b-to-boost-cell-therapy\/","title":{"rendered":"AstraZeneca to Buy EsoBiotec for $1B to Boost Cell Therapy"},"content":{"rendered":"<h2 data-start=\"85\" data-end=\"161\">Biotech Giant Expands Cell Therapy Capabilities with ENaBL Platform<\/h2>\n<p data-start=\"163\" data-end=\"478\">In a major move to strengthen its cell and gene therapy portfolio, AstraZeneca has announced the acquisition of biotechnology firm EsoBiotec for up to $1 billion. The deal includes a $425 million upfront payment and an additional $575 million tied to regulatory and development milestones.<\/p>\n<p data-start=\"480\" data-end=\"767\">The acquisition will give AstraZeneca access to EsoBiotec\u2019s Engineered NanoBody Lentiviral (ENaBL) platform, a groundbreaking technology that enables rapid genetic modification of immune cells inside the body, drastically reducing the time required for cell therapy treatments.<\/p>\n<h2 data-start=\"774\" data-end=\"833\">Revolutionizing Cell Therapy with ENaBL Technology<\/h2>\n<p data-start=\"835\" data-end=\"995\">The ENaBL platform represents a significant breakthrough in cell therapy, offering a faster and more efficient alternative to traditional methods.<\/p>\n<ul data-start=\"997\" data-end=\"1533\">\n<li data-start=\"997\" data-end=\"1145\">Traditional cell therapy treatments require weeks of processing, involving the extraction, modification, and reinfusion of immune cells.<\/li>\n<li data-start=\"1146\" data-end=\"1332\">EsoBiotec\u2019s ENaBL technology eliminates this extended process by genetically modifying immune cells directly inside the body, cutting treatment times down to minutes.<\/li>\n<li data-start=\"1333\" data-end=\"1533\">This platform has the potential to enhance patient access to life-saving therapies while reducing treatment costs and logistical challenges associated with conventional cell therapies.<\/li>\n<\/ul>\n<p data-start=\"1535\" data-end=\"1729\">\u201cThis acquisition aligns with AstraZeneca\u2019s long-term strategy to expand our capabilities in cell and gene therapy and bring next-generation treatments to patients faster,\u201d the company stated.<\/p>\n<h2 data-start=\"1736\" data-end=\"1779\">Deal Structure and Financial Terms<\/h2>\n<p data-start=\"1781\" data-end=\"1885\">AstraZeneca will acquire 100% of EsoBiotec\u2019s outstanding equity on a cash and debt-free basis.<\/p>\n<ul data-start=\"1887\" data-end=\"2267\">\n<li data-start=\"1887\" data-end=\"1955\">$425 million upfront payment will be made upon deal closing.<\/li>\n<li data-start=\"1956\" data-end=\"2084\">Up to $575 million will be paid in contingent milestones based on development progress and regulatory approvals.<\/li>\n<li data-start=\"2085\" data-end=\"2167\">The deal is expected to close in Q2 2025, subject to regulatory approvals.<\/li>\n<li data-start=\"2168\" data-end=\"2267\">AstraZeneca confirmed that the acquisition will not impact its financial guidance for 2025.<\/li>\n<\/ul>\n<h2 data-start=\"2274\" data-end=\"2338\">AstraZeneca\u2019s Strategic Push into Cell and Gene Therapy<\/h2>\n<p data-start=\"2340\" data-end=\"2518\">AstraZeneca has been actively expanding its presence in cell therapy, positioning itself among global pharmaceutical leaders in oncology, immunology, and rare diseases.<\/p>\n<p data-start=\"2520\" data-end=\"2561\">\u2714 Prior Investments in Cell Therapy<\/p>\n<ul data-start=\"2562\" data-end=\"2948\">\n<li data-start=\"2562\" data-end=\"2666\">2022: AstraZeneca partnered with Cellectis to develop CAR-T therapies for blood cancers.<\/li>\n<li data-start=\"2667\" data-end=\"2824\">2023: The company launched a $2 billion collaboration with Quell Therapeutics to develop regulatory T-cell therapies for autoimmune diseases.<\/li>\n<li data-start=\"2825\" data-end=\"2948\">2024: AstraZeneca announced plans to expand its manufacturing facilities for gene and cell therapy development.<\/li>\n<\/ul>\n<p data-start=\"2950\" data-end=\"3007\">\u2714 How EsoBiotec Strengthens AstraZeneca\u2019s Portfolio<\/p>\n<ul data-start=\"3008\" data-end=\"3271\">\n<li data-start=\"3008\" data-end=\"3115\">The ENaBL platform complements AstraZeneca\u2019s existing work in immuno-oncology and gene editing.<\/li>\n<li data-start=\"3116\" data-end=\"3271\">The acquisition aligns with AstraZeneca\u2019s broader push to shorten therapy development timelines and make personalized medicine more accessible.<\/li>\n<\/ul>\n<h2 data-start=\"3278\" data-end=\"3329\">AstraZeneca and EsoBiotec?<\/h2>\n<p data-start=\"3331\" data-end=\"3475\">With regulatory approvals expected by mid-2025, the integration of EsoBiotec into AstraZeneca\u2019s global operations will be closely watched.<\/p>\n<p data-start=\"3477\" data-end=\"3502\">\u2714 Short-term Focus:<\/p>\n<ul data-start=\"3503\" data-end=\"3690\">\n<li data-start=\"3503\" data-end=\"3584\">Ensuring regulatory approvals and finalizing the acquisition process.<\/li>\n<li data-start=\"3585\" data-end=\"3690\">Advancing ENaBL-based therapies into clinical trials for oncology and rare disease treatment.<\/li>\n<\/ul>\n<p data-start=\"3692\" data-end=\"3717\">\u2714 Long-term Impact:<\/p>\n<ul data-start=\"3718\" data-end=\"3900\">\n<li data-start=\"3718\" data-end=\"3798\">Bringing rapid cell therapies to market, addressing unmet medical needs.<\/li>\n<li data-start=\"3799\" data-end=\"3900\">Potential expansion of the ENaBL platform to autoimmune diseases and infectious diseases.<\/li>\n<\/ul>\n<p data-start=\"3902\" data-end=\"4111\" data-is-last-node=\"\" data-is-only-node=\"\">The acquisition marks a major step in AstraZeneca\u2019s evolution into a leading innovator in next-generation cell and gene therapy, signaling faster, more accessible treatments for patients worldwide.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biotech Giant Expands Cell Therapy Capabilities with ENaBL Platform In a major move to strengthen its cell and gene therapy portfolio, AstraZeneca has announced the acquisition of biotechnology firm EsoBiotec for up to $1 billion. The deal includes a $425 million upfront payment and an additional $575 million tied to regulatory and development milestones. The [&hellip;]<\/p>\n","protected":false},"author":4,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1365,1362],"tags":[],"ppma_author":[1331],"class_list":{"0":"post-5402","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-business-news","8":"category-finance-and-economy-news"}," _eael_post_view_count":0,"authors":[{"term_id":1331,"user_id":4,"is_guest":0,"slug":"sourabh","display_name":"Sourabh Sharma","avatar_url":{"url":"https:\/\/trending.niftytrader.in\/wp-content\/uploads\/2025\/11\/Sourabh-Sharma.png","url2x":"https:\/\/trending.niftytrader.in\/wp-content\/uploads\/2025\/11\/Sourabh-Sharma.png"},"0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":""}],"_links":{"self":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts\/5402","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/comments?post=5402"}],"version-history":[{"count":1,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts\/5402\/revisions"}],"predecessor-version":[{"id":5404,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts\/5402\/revisions\/5404"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/media\/5403"}],"wp:attachment":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/media?parent=5402"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/categories?post=5402"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/tags?post=5402"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/ppma_author?post=5402"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}